Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
July 19 2021 - 8:00AM
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage
biopharmaceutical company focused on developing drugs that
meaningfully improve the lives of patients with rare
cardiopulmonary disease, today announced the appointment of Allison
Dorval, chief financial officer of Voyager Therapeutics, Inc.
(“Voyager”), as a member of Aerovate’s Board of Directors.
"The addition of Allison’s corporate finance and
broad operating expertise to our Board of Directors will serve
Aerovate well as we seek to develop and commercialize AV-101, our
novel dry powder inhaled formulation of the drug imatinib, for the
treatment of pulmonary arterial hypertension, also known as PAH,”
said Timothy Noyes, chief executive officer of Aerovate. “We are
thrilled to welcome her to Aerovate and to benefit from her deep
experience, which includes providing financial stewardship for
publicly traded companies.”
Ms. Dorval currently serves as chief financial
officer and principal finance and accounting officer at Voyager
Therapeutics, and is a member of the Board of Directors of Puma
Biotechnology, Inc. She has over twenty years of corporate finance,
accounting and operating experience, including 14 years of life
sciences executive finance experience. Prior to Voyager, Ms. Dorval
served as vice president, controller, at Juniper Pharmaceuticals,
Inc., and as chief financial officer at Insulet Corporation, where
she led financial planning, reporting and accounting. Previously,
Ms. Dorval held corporate finance positions with iBasis, Inc. and
Digitas Inc. Ms. Dorval is a certified public accountant and began
her career in public accounting at PricewaterhouseCoopers LLP,
where she held positions of increasing responsibility and scope.
Ms. Dorval obtained a Bachelor of Science in Business
Administration from the University of Vermont.
“Joining the Aerovate Board of Directors
presents a unique opportunity to contribute to the development of a
novel approach to treating pulmonary arterial hypertension,”
commented Ms. Dorval. “People suffering from PAH face a poor
prognosis, despite the availability of multiple approved therapies.
I am excited about helping Aerovate deliver a potential new
treatment option for these underserved patients.”
About Aerovate Therapeutics, Inc.
Aerovate is a clinical stage biopharmaceutical
company focused on developing drugs that meaningfully improve the
lives of patients with rare cardiopulmonary disease. Aerovate's
initial focus is on advancing AV-101, its dry powder inhaled
formulation of the drug imatinib for the treatment of pulmonary
arterial hypertension, or PAH.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
express or implied statements regarding the advancement of our
clinical programs, our expectations of the therapeutic benefits
related thereto, and our growth as a company and the anticipated
contribution of the members of our board of directors to our
operations and progress. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
advancement of our clinical program for AV-101, the expected impact
and contribution of our Board of Directors and executives to our
business, and other risks identified in our filings with the
Securities and Exchange Commission (“SEC”), including our
Registration Statement on Form S-1, and subsequent filings with the
SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Contact:
Julio Cantre
Info@aerovatetx.com
202.930.4762
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jul 2023 to Jul 2024